We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Axol Bioscience Appoints Chief Business Officer

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Axol Bioscience has announced the appointment of Sanj Kumar to the position of Chief Business Officer, an experienced and successful life science executive, well known for establishing and growing life science businesses, most recently at DiscoveRx ltd.

“Axol has built a strong position in the provision of disease relevant cell based assays to the drug discovery industry and has plans to significantly expand its product portfolio, broaden its customer base and deepen it’s relationships with key opinion leaders within pharmaceutical research departments globally” said Dr Yichen Shi CEO of Axol Bioscience. “Our desire to be the drug discovery industry's most trusted source of disease relevant cell based systems, requires us to strengthen our commercial leadership skills and Sanj has an impressive track record, in this area. He will play a key role in leveraging the promise of stem cell derived disease models.”

As Senior Vice President of Sales and Marketing at DiscoveRx ltd, Mr Sanj Kumar was instrumental in establishing and growing their European business, but in addition has a strong scientific background having studied at the Institute of Neurology, London, then continuing his research career at Nagoya University, Nagoya.

He is also Chairman of the UK’s ELRIG organization, a voluntary organization that organizes science led meetings for the drug discovery community, where his role is to lead the ELRIG board and ensure the provision of cutting edge science to a seven thousand people strong drug discovery community.